high-titer anti-SARS-CoV-2 convalescent plasma

High-titer anti-SARS-CoV-2 convalescent plasma is a blood product collected from individuals who have recovered from COVID-19 and have developed a strong immune response, as indicated by elevated levels of antibodies against SARS-CoV-2. The therapy involves transfusing this antibody-rich plasma into patients with active COVID-19 infection—especially those who are immunocompromised or at risk for severe disease progression. The mechanism of action is passive immunization; the transferred antibodies can neutralize the virus and may help reduce viral load and severity of illness. High titer is defined by specific antibody thresholds (e.g., ≥1,280 AU/mL on Abbott ARCHITECT assay or >55 RU/mL on EUROIMMUN assay). This therapy has been used both in inpatient and outpatient settings for patients with weakened immune systems[1][3][5]. Clinical studies suggest it may provide benefit in reducing mortality among immunocompromised patients when administered early or in combination with antiviral agents[4][7].

Other names

high-titer COVID-19 convalescent plasmahigh-titer CPCCP (COVID-19 convalescent plasma)whole blood-derived high-titer anti-SARS-CoV-2 convalescent plasmaapheresis-derived high-titer anti-SARS-CoV-2 convalescent plasma